05.19.22
BioMoti Ltd has signed an agreement with a global pharmaceutical company to collaborate on the development of its lead ovarian cancer candidate, BMT101, to clinical phase 2a proof-of-concept.
The collaboration agreement provides access to the partner company’s expertise including its proprietary commercial manufacturing technology and an option for the global pharmaceutical company to license BMT101 in specific territories.
BMT101, BioMoti’s lead candidate for the unmet need in ovarian cancer, is a new type of tumor-targeted treatment consisting of CD95-coated long-acting paclitaxel-loaded microparticles. BMT101 has shown very encouraging preclinical proof-of-concept results compared to the clinical standard-of-care, paclitaxel, including over 10-fold increases in drug concentration in tumours, 65-fold reductions in tumour burden, a 4-fold increase in survival and a reduction in toxicity.
Beadle, MBBCh, MBA, brings a wealth of experience and knowledge in the development of clinical stage biotech companies. He was previously founding chief executive officer of PsiOxus Therapeutics, founder and chief medical officer of PowderMed, entrepreneur-in-residence at Imperial Innovations and Vice President of Global Medical Operations at GlaxoSmithKline. To date, he has raised in excess of $150 million and realized transaction values in excess of $300 million within the biotech industry.
Dr. Davidson Ateh, CEO of BioMoti, said: “We are extremely pleased to have secured a strong development partner with commercial manufacturing experience on similar products to BMT101. The company’s expertise includes developing clinical candidates to market launch, offering a unique opportunity for us to address the significant medical need in the treatment of ovarian cancer patients.”
He added, “We are very grateful for the contributions of our departing Chairman, Dr Keith Powell, who has stepped down to focus on other duties. He remains a good friend and trusted advisor. We are delighted to welcome Dr John Beadle at this crucial stage of our development. John is a remarkable leader within our industry with an impressive track record and whose impact is already being felt as we move forward with the next stages of clinical development.”
Beadle commented: “I am delighted to join BioMoti at this exciting time as we transition the technology from pre-clinical research into a clinical development programme, thus bringing the BioMoti technology one step closer to becoming a treatment for patients with ovarian cancer.”
The collaboration agreement provides access to the partner company’s expertise including its proprietary commercial manufacturing technology and an option for the global pharmaceutical company to license BMT101 in specific territories.
BMT101, BioMoti’s lead candidate for the unmet need in ovarian cancer, is a new type of tumor-targeted treatment consisting of CD95-coated long-acting paclitaxel-loaded microparticles. BMT101 has shown very encouraging preclinical proof-of-concept results compared to the clinical standard-of-care, paclitaxel, including over 10-fold increases in drug concentration in tumours, 65-fold reductions in tumour burden, a 4-fold increase in survival and a reduction in toxicity.
Dr. John Beadle Joins BoD as Chairman
BioMoti also announces that Dr. John Beadle has joined its Board of Directors as chairman, replacing Dr. Keith Powell who has stepped down.Beadle, MBBCh, MBA, brings a wealth of experience and knowledge in the development of clinical stage biotech companies. He was previously founding chief executive officer of PsiOxus Therapeutics, founder and chief medical officer of PowderMed, entrepreneur-in-residence at Imperial Innovations and Vice President of Global Medical Operations at GlaxoSmithKline. To date, he has raised in excess of $150 million and realized transaction values in excess of $300 million within the biotech industry.
Dr. Davidson Ateh, CEO of BioMoti, said: “We are extremely pleased to have secured a strong development partner with commercial manufacturing experience on similar products to BMT101. The company’s expertise includes developing clinical candidates to market launch, offering a unique opportunity for us to address the significant medical need in the treatment of ovarian cancer patients.”
He added, “We are very grateful for the contributions of our departing Chairman, Dr Keith Powell, who has stepped down to focus on other duties. He remains a good friend and trusted advisor. We are delighted to welcome Dr John Beadle at this crucial stage of our development. John is a remarkable leader within our industry with an impressive track record and whose impact is already being felt as we move forward with the next stages of clinical development.”
Beadle commented: “I am delighted to join BioMoti at this exciting time as we transition the technology from pre-clinical research into a clinical development programme, thus bringing the BioMoti technology one step closer to becoming a treatment for patients with ovarian cancer.”
